iCAD, INC. (NASDAQ:ICAD) Files An 8-K Results of Operations and Financial Condition

Item2.02

On March8, 2017, iCAD, Inc. (the Company) issued a press release
announcing its financial results for the fourth quarter and
fiscal year ending December31, 2016. A copy of the Companys press
release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.

Exhibit 99.1 referenced below is being furnished to Item2.02, is
not to be considered filed under the Securities Exchange Act of
1934, as amended (Exchange Act), and shall not be incorporated by
reference into any of the Companys previous or future filings
under the Securities Act of 1933, as amended, or the Exchange
Act.

(d) Exhibits.

About iCAD, INC. (NASDAQ:ICAD)

iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.

iCAD, INC. (NASDAQ:ICAD) Recent Trading Information

iCAD, INC. (NASDAQ:ICAD) closed its last trading session up +0.46 at 4.03 with 310,650 shares trading hands.